Elicio Therapeutics Announces Positive Phase 2 AMPLIFY-7P Results for Camupepimut

Article summary

Elicio Therapeutics reported positive results from its randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) for the treatment of KRAS-driven pancreatic cancer, showing a significant reduction in the risk of recurrence or death.